8ijs
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==anti-VEGF nanobody mutant== | |
| + | <StructureSection load='8ijs' size='340' side='right'caption='[[8ijs]], [[Resolution|resolution]] 1.75Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[8ijs]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8IJS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8IJS FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.752Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8ijs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8ijs OCA], [https://pdbe.org/8ijs PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8ijs RCSB], [https://www.ebi.ac.uk/pdbsum/8ijs PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8ijs ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Wet age-related macular degeneration (wet AMD) is the most common cause of blindness, and chronic intravitreal injection of anti-vascular endothelial growth factor (VEGF) proteins has been the dominant therapeutic approach. Less intravitreal injection and a prolonged inter-injection interval are the main drivers behind new wet AMD drug innovations. By rationally engineering the surface residues of a model anti-VEGF nanobody, we obtained a series of anti-VEGF nanobodies with identical protein structures and VEGF binding affinities, while drastically different crystallization propensities and crystal lattice structures. Among these nanobody crystals, the P2(1)2(1)2(1) lattice appeared to be denser and released protein slower than the P1 lattice, while nanobody crystals embedding zinc coordination further slowed the protein release rate. The polymorphic protein crystals could be a potentially breakthrough strategy for chronic intravitreal administration of anti-VEGF proteins. | ||
| - | + | Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.,Zhu S, Fan S, Tang T, Huang J, Zhou H, Huang C, Chen Y, Qian F Bioeng Transl Med. 2023 May 4;8(6):e10523. doi: 10.1002/btm2.10523. eCollection , 2023 Nov. PMID:38023710<ref>PMID:38023710</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: Qian | + | <div class="pdbe-citations 8ijs" style="background-color:#fffaf0;"></div> |
| - | [[Category: Zhu | + | == References == |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Qian F]] | ||
| + | [[Category: Zhu SQ]] | ||
Current revision
anti-VEGF nanobody mutant
| |||||||||||
